NUVL
Nuvalent IncKey Statistics
About Nuvalent Inc
Nuvalent Inc. is a pioneering clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients with genetically defined diseases. Leveraging its proprietary drug discovery platform, the company aims to create innovative treatments that specifically target genetic mutations responsible for tumor growth, thereby improving patient outcomes and minimizing side effects. With a robust pipeline of highly selective therapies, Nuvalent is strategically positioned within the precision oncology market, making it well-equipped to seize emerging opportunities in the rapidly evolving biotechnology sector. The company’s relentless commitment to advancing cancer treatment underscores its potential to significantly impact patient care in oncology.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -36.70% |
| Return on Assets | -20.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $15.96 |
| Price-to-Book | 6.65 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -22.26 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $73.18M |
| Float | $48.66M |
| % Insiders | 2.73% |
| % Institutions | 111.41% |